|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.4790 - 0.5340|
|52 Week Range||0.1799 - 0.6887|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On May 21, 2018, Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH, 2607.HK) announced that the Company entered into a Share Purchase Agreement with Takeda Pharma AG. Pursuant to the agreement, Shanghai Pharma, through its Hong Kong subsidiary Shanghai Pharmaceuticals (HK), will acquire 100% equity interest of a wholly-owned subsidiary of Takeda AG with a consideration of US$144 million, resulting in its indirect acquisition of 26.34% shares of Techpool Bio-pharma Co., Ltd. (Techpool). Upon completion of the Proposed Acquisition, the shareholding in Techpool by Shanghai Pharma will be increased from 40.80% to 67.14% and Shanghai Pharma would achieve absolute control of Techpool.
DiaMedica Therapeutics Inc. (“DiaMedica”) (TSX VENTURE:DMA) (DMCAF), a clinical stage biopharmaceutical company focused on improving lives of patients with neurological and kidney diseases associated with low KLK1 levels, announced receipt of the final minutes from an in-person Type B meeting, with the Office of Drug Evaluation, Cardiovascular and Renal Division, of the U.S. Food and Drug Administration (FDA). The objective of the meeting was to gain feedback and recommendations from the FDA on DiaMedica’s planned clinical study of DM199 in patients with chronic kidney disease (CKD).
MINNEAPOLIS, MN / ACCESSWIRE / April 3, 2018 / DiaMedica Therapeutics Inc. (''DiaMedica'') (TSX-V: DMA) (OTCQB: DMCAF), today announced that Mr. Rick Pauls, President and CEO, will present at The MicroCap ...
On Dec. 13, 2017, DiaMedica (TSX:DMA.V) announced a non-brokered private placement. Per the news release, each unit included one common share and one-half of one common share purchase warrant. This share offering was offered on a non-brokered private placement basis to accredited investors.
Recently, DiaMedica entered into a non-binding term sheet with a large China-based pharmaceutical company for potential licensing rights in China. The Company is continuing ongoing discussions with potential partners in Asia.
On October 27, 2017, DiaMedica Therapeutics (DMA.V) announced that the company received approximately USD$605,263 in gross proceeds from the early exercise of 2,631,579 April 2017 warrants at USD$0.23 (CAD$0.31) per share. Also, in April, DiaMedica completed a non-brokered private placement with a prominent U.S. investor. In that placement, DiaMedica issued 10,526,315 units to the investor at an issue price of USD$0.19 (CAD$0.25) per unit.
On September 11, 2017, DiaMedica (DMA.V) announced the initiation of a Phase II REMEDY clinical trial assessing the safety, tolerability, and markers of therapeutic activity of DM199 (recombinant human KLK1) in patients suffering from acute ischemic stroke (AIS). REMEDY is a multi-center, double-blind, randomized, placebo-controlled Phase II clinical trial investigating DM199 treatment in patients who have suffered a moderate to moderately severe acute ischemic stroke.